Potency is one of the most important indexes of inactivated vaccines. A number of methods have been established to assay the potency, of which the NIH test and single-dose mouse protection test are the “prescribed methods”. Here, we report a method to semi-quantitatively assay the potency of an inactivated rabies vaccine, which uses fewer animals and takes less time to complete. Depending on the quality requirements of a vaccine (e.g. minimum potency), a rabies reference vaccine is, for example, diluted to the minimum potency, and 50 μL of the dilution is taken to inoculate 10 mice. The same amount of the test rabies vaccine is inoculated into another 10 mice. After two weeks, all mice are bled and serum samples are assayed for viral neutralizing antibody by the fluorescent antibody virus neutralization (FAVN) test. By comparing the median and interquartile range of antibody titers of the reference vaccine with those of the test vaccine, the test vaccine potency can be semi-quantitatively judged as to whether it is in accord with the required quality. The reliability of this method was also confirmed in dogs. The procedure can be recommended for batch potency testing during inactivated rabies vaccine production.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Bruckner L, Kihm U. 1986. Alternatives for potency testing of veterinary vaccines: rabies vaccine as a model. Dev Biol Stand, 64: 93–97.
Barth R, Diderrich G, Weinmann E. 1988. NIH test, a problematic method for testing potency of inactivated rabies vaccine. Vaccine, 6(4): 369–377.
Cliquet F, Aubert M, Sagne L. 1998. Development of a fluorescent antibody virus neutralization test (FAVN test) for the quantitation of rabies-neutralizing antibody. J Immunol Mthods, 212(1): 79–87.
Ferguson M, Heath A. 1992. Report of a collaborative study to assess the determination of glycoprotein antigen content of rabies vaccines for human use. Biologicals, 20: 143–154.
Ferguson M, Schild G C. 1982. A single-radial-immunodiffusion technique for the assay of rabies glycoprotein antigen: application to potency tests of vaccines against rabies. J Gen Virol, 59(1): 197–201.
Fernández I, Peña A, Teso N D, et al. 2010. Clinical Biochemistry Parameters in C57BL/6J Mice after Blood Collection from the Submandibular Vein and Retroorbital Plexus. J Am Assoc Lab Anim Sci, 49(2): 202–206.
Fitzgerald E A, Gallagher M, Hunter W S, et al. 1978. Use of the antibody assay in immunized mice for the determination of rabies vaccine potency. Dev Biol Stand, 40: 183–186.
Fournier-Caruana J, Poirier B, Haond G, et al. 2003. Inactivated rabies vaccine control and release: use of an ELISA method. Biologicals, 31(1): 9–16.
Gamoh K, Senda M, Itoh O, et al. 1996. Use of ELISA for in vitro potency test of rabies vaccines for animal use. Biologicals, 24(2): 95–101.
Gaddis G M, Gaddis M L. 1990. Introduction to biostaticstics: Part 2, Descriptive statistics. Ann Emerg Med, 19(3): 309–315.
Gamoh K, Shimazaki Y, Senda M, et al. 2003. Establishment of a potency test by ELISA for a rabies vaccine for animal use in Japan. J Vet Med Sci, 65(6): 685–688.
Habel K. 1996 Laboratory techniques in rabies: Habel test for potency. Monogr Ser World Health Organ, (23): 369–373.
Hu R L, Fooks A R, Zhang S F, et al. 2008. Inferior rabies vaccine quality and low immunization coverage in dogs (Canis familiaris) in China. Epidemiol Infect, 136(11): 1556–1563.
Krämer B, Bruckner L, Daas A, et al. 2010. Collaborative study for validation of a serological potency assay for rabies vaccine (inactivated) for veterinary use. Pharmeur Bio Sci Notes, 2010(2): 37–55.
Krämer B, Schildger H, Behrensdorf-Nicol H A, et al. 2009. The rapid fluorescent focus inhibition test is a suitable method for batch potency testing of inactivated rabies vaccines. Biologicals, 37(2):119–126.
Lafon M, Perrin P, Versmisse P, et al. 1985. Use of a monoclonal antibody for quantification of rabies vaccine glycoprotein by enzyme immunoassay. J Biol Stand, 13: 295–301.
Lindbladh C, Mosbach K, Bülow L. 1993. Use of genetically prepared enzyme conjugates in enzyme immunoassay. Trends Biochem Sci, 18(8): 279–283.
Monograph European Pharmacopoeia. 1985. Vaccinum rabiei inactivatum ad usum veterinarium.In: Monograph European Pharmacopoeia, 2nd Ed. pp451.
Mousli M, Turki I, Kharmachi H, et al. 2007. Recombinant single-chain Fv antibody fragment-alkaline phosphatase conjugate: a novel in vitro tool to estimate rabies viral glycoprotein antigen in vaccine manufacture. J Virol Methods, 146(1–2): 246–256.
Nagarajan T, Reddy G S, Mohana Subramanian B, et al. 2006. A simple immuno-capture ELISA to estimate rabies viral glycolprotein antigen in vaccine manufacture. Biologicals, 34(1): 21–27.
Nimmagadda S V, Aavula S M, Biradhar N, et al. 2010. Recombinant diabody-based immunocapture enzyme-linked immunosorbent assay for quantification of rabies virus glycoprotein. Clin Vaccine Immunol, 17(8): 1261–1268.
Perrin P, Morgeaux S, Sureau P. 1990. In vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody. Biologicals, 18: 321–330.
Rooijakkers E, Groen J, Uittenbogaard J, et al. 1996. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines. Dev Biol Stand, 86: 137–145.
Seligmann EB Jr. 1996. Laboratory techniques in rabies. Potency-test requirements of the United State National Institutes of Health (NIH). Monogr Ser World Health Organ, (23): 360–368.
World Health Organization. 2005. WHO Expert Consultation on Rabies. In: First Report WHO Technical Report Series No. 931. Geneva: World Health Organization. pp31–56.
Wu X F, Hu R L, Zhang Y Z, et al. 2009. Reemerging rabies and lack of systemic surveillance in People’s Republic of China. Emerg Infect Dis, 15(8): 1159–1164.
Wunderli P S, Dreesen D W, Miller T J, et al. 2006. The rabies peripheral challenge test: more accurate determination of vaccine potency. Vaccine, 24: 7115–7123.
Wunderli P S, Dreesen D W, Miller T J, et al. 2003. Effects of vaccine route and dosage on protection from rabies after intracerebral challenge in mice. Am J Vet Res, 64(4): 491–498.
Wunderli P S, Shaddock J H, Schmid D S, et al. 1991. The protective role of humoral neutralizing antibody in the NIH potency test for rabies vaccines. Vaccine, 9: 638–642.
Foundation items: The research was funded by the China National “863” Program (Approval No.2011AA10A212) and Special Fund for Agro-Scientific Research in the Public Interest (Approval No. 201203056).
Rights and permissions
About this article
Cite this article
Liu, Y., Zhang, S., Zhang, F. et al. A semi-quantitative serological method to assess the potency of inactivated rabies vaccine for veterinary use. Virol. Sin. 27, 259–264 (2012). https://doi.org/10.1007/s12250-012-3260-y
- Inactivated vaccine
- Potency assay
- Semi-quantitative method